Gufic Biosciences Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Gufic Biosciences reported Q1 FY27 revenue of INR260.8 crores versus INR226.9 crores in Q1 FY26, with EBITDA margin expanding to 18.09% from 14.6%. Management discussed progress at the Indore facility including depot and microsphere suite completion, a CMO partnership with Hetero for semaglutide, and a shift in international markets from a distributor-led to a front-end model. Management also addressed capacity utilization trends at Indore and reiterated a growth commitment for the company overall.
Gufic Biosciences reported Q4 FY26 revenue of around INR252 crores, its strongest quarter ever, with EBITDA margin expanding to 17.73% from 13.17% a year earlier and PAT more than doubling year-over-year. Full year FY26 revenue was INR940.50 crores versus INR820 crores in FY25, with EBITDA of INR152.9 crores and PAT of INR63.2 crores. Management attributed the quarterly improvement to the Indore facility reaching EBITDA breakeven at 30% capacity utilization, a working capital reset in the Critical Care cluster, and growth in the women's health and aesthetics platforms.